Adaptimmune stock plunges after announcing Nasdaq delisting plans
SOLANA BEACH, Calif. - Artelo Biosciences, Inc. (NASDAQ:ARTL) announced positive clinical data from two of its development programs at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit in Boston.
The company presented expanded data from its lead Fatty Acid Binding Protein 5 (FABP5) inhibitor, ART26.12, showing the compound was safe and well-tolerated at single doses up to 1050 milligrams in healthy volunteers. The Single Ascending Dose study demonstrated predictable linear dose exposure and indicated potential dosing flexibility in either fed or fasted states. The stock, currently trading near its 52-week low of $4.00, has seen increased investor attention following these developments. InvestingPro data shows multiple additional technical and fundamental indicators that could impact trading decisions.
Artelo also shared interim data from the Phase 2 portion of its Cancer Appetite Recovery Study (CAReS) for ART27.13, a dual cannabinoid agonist being developed for cancer-related anorexia. Initial findings showed patients receiving up to 1300 micrograms daily gained over 6% in weight on average, while placebo participants lost an additional 5%. The safety profile was reported as well-tolerated.
"ART27.13 is uniquely positioned as the most clinically advanced small-molecule, orally administered once-daily treatment in development for cancer anorexia," said Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, who presented the data. Cancer anorexia affects up to 80% of late-stage cancer patients, with no currently approved treatments in the US, UK or EU.
ART26.12 is being developed as a non-opioid, non-steroidal analgesic, initially targeting chemotherapy-induced peripheral neuropathy. ART27.13, originally developed by AstraZeneca, has been studied in seven clinical trials with over 280 participants.
The announcements were made during a presentation at the summit taking place October 15-16, 2025, according to the company’s press release statement. Investors anticipating the company’s next earnings report, scheduled for November 12, 2025, can access comprehensive financial analysis and additional insights through InvestingPro, which features over 10 key investment tips for ARTL stock.
In other recent news, Artelo Biosciences, Inc. completed a public offering, raising approximately $2 million in gross proceeds. The offering involved 441,210 shares of common stock priced at $4.40 per share, along with pre-funded warrants for 13,335 shares at $4.399 each. This move followed the announcement and pricing of the offering, with R.F. Lafferty & Co., Inc. acting as the sole book-running manager. Additionally, interim data from Artelo’s Phase 2 Cancer Appetite Recovery Study indicated that patients treated with ART27.13 experienced a 6% weight gain over 12 weeks, contrasting with a 5% weight loss in placebo patients. Another development includes the publication of preclinical data showing that Artelo’s CBD:tetramethylpyrazine cocrystal, ART12.11, demonstrated improved efficacy in treating stress-induced depression and anxiety compared to CBD alone. The study, conducted with Western Ontario University, highlighted ART12.11’s superior oral bioavailability. These developments mark significant progress in Artelo’s clinical and preclinical research efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.